O. Ottman

Analysis of genomic breakpoints in p190 and p210 BCR–ABL indicate distinct mechanisms of formation

J Score, Marı́a José Calasanz, O. Ottman et al. · Leukemia · 2010 · 64 citations

Life Sciences, Genetics, Molecular Genetics +7

Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 ‘START-L’ study

Steven Coutré, Giovanni Martinelli, Hervé Dombret et al. · Journal of Clinical Oncology · 2006 · 31 citations

Medicine, Hematology, Pharmacology +15

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

Gabriela M. Baerlocher, Elisabeth Oppliger Leibundgut, Christina Ayran et al. · Blood · 2012 · 23 citations

Medicine, Hematology, Pharmacology +6

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

Hagop M. Kantarjian, O. Ottman, Jörge E. Cortes et al. · Blood · 2005 · 20 citations

Medicine, Oncology, Pharmacology +6

AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study

Andrew M. Brunner, Uma Borate, Jordi Esteve et al. · Clinical Lymphoma Myeloma & Leukemia · 2020 · 18 citations

Medicine, Hematology, Oncology +17